CUSTIRSEN (OGX-011): A SECOND-GENE RATION ANTISENSE INHIBITOR OF CLUSTERIN FOR THE TREATMENT OF CANCER

被引：0
|
作者：
Gleave, Martin [1 ,2 ,3 ]
机构：
[1] Univ British Columbia, Vancouver Prostate Ctr, Vancouver, BC V5Z 1M9, Canada
[2] Univ British Columbia, Dept Urol Sci, Vancouver, BC V5Z 1M9, Canada
[3] OncoGenex Technol, Vancouver, BC, Canada
来源：
JOURNAL OF ANDROLOGY | 2009年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
摘要：
引用
收藏
页码：14 / 14
页数：1
相关论文
共 22 条
  • [1] Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancer
    Chi, Kim N.
    Zoubeidi, Amina
    Gleave, Martin E.
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2008, 17 (12) : 1955 - 1962
  • [2] Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin in development for the treatment of prostate cancer
    Zielinski, Robert
    Chi, Kim N.
    [J]. FUTURE ONCOLOGY, 2012, 8 (10) : 1239 - 1251
  • [3] Custirsen (OGX-011): Clusterin Inhibitor in Metastatic Prostate Cancer
    Sohaib Al-Asaaed
    Eric Winquist
    [J]. Current Oncology Reports, 2013, 15 : 113 - 118
  • [4] Custirsen (OGX-011): Clusterin Inhibitor in Metastatic Prostate Cancer
    Al-Asaaed, Sohaib
    Winquist, Eric
    [J]. CURRENT ONCOLOGY REPORTS, 2013, 15 (02) : 113 - 118
  • [5] Drug evaluation: OGX-011, a clusterin-inhibiting antisense oligonucleotide
    Schmitz, Gerd
    [J]. CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2006, 8 (06) : 547 - 554
  • [6] CLUSTERIN ANTISENSE INHIBITOR OGX-011 SYNERGIZES ACTIVITY OF SECOND GENERATION ANTI-ANDROGEN, MDV3100, IN CASTRATE RESISTANT PROSTATE CANCER MODEL
    Matsumoto, Hiroaki
    Kuruma, Hidetoshi
    Zoubeidi, Amina
    Fazli, Ladan
    Gleave, Martin
    [J]. JOURNAL OF UROLOGY, 2011, 185 (04): : E52 - E53
  • [7] An evaluation of clusterin antisense inhibitor OGX-011 in combination with the second-generation antiandrogen MDV3100 in a castrate-resistant prostate cancer model.
    Matsumoto, H.
    Kuruma, H.
    Zoubeidi, A.
    Fazli, L.
    Gleave, M. E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] A phase I study of OGX-011, a 2′-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer
    Chi, Kim N.
    Siu, Lillian L.
    Hirte, Hal
    Hotte, Sebastien J.
    Knox, Jennifer
    Kollmansberger, Christian
    Gleave, Martin
    Guns, Emma
    Powers, Jean
    Walsh, Wendy
    Tu, Dongsheng
    Eisenhauer, Elizabeth
    [J]. CLINICAL CANCER RESEARCH, 2008, 14 (03) : 833 - 839
  • [9] A phase I study of a second generation antisense oligonucleotide to clusterin (OGX-011) in combination with docetaxel: NCICCTG IND. 154.
    Chi, KN
    Eisenhauer, E
    Siu, L
    Hirte, H
    Hotte, SJ
    Chia, S
    Knox, J
    Guns, E
    Powers, J
    Gleave, ME
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 213S - 213S
  • [10] A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer
    Chi, KN
    Eisenhauer, E
    Fazli, L
    Jones, EC
    Goldenberg, SL
    Powers, J
    Tu, DS
    Gleave, ME
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (17) : 1287 - 1296
123